Celltrion sets sights on 2017 for EU and US rituximab biosimilar success
Celltrion is confident that 2017 will bring European approval and a US filing for Truxima, after achieving regulatory success for the Rituxan biosimilar in Korea.
Archives for November 25, 2016
Kymab secures $100m and two new Chinese backers
Antibody developer Kymab has secured $100m from existing backers and new China-based investors Hepalink and ORI Healthcare Fund.